189 related articles for article (PubMed ID: 27079872)
1. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.
Carlsson L; Larsson A; Lindman H
Ups J Med Sci; 2009; 114(2):116-20. PubMed ID: 19396699
[TBL] [Abstract][Full Text] [Related]
3. Can thymidine kinase levels in breast tumors predict disease recurrence?
O'Neill KL; Hoper M; Odling-Smee GW
J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
[TBL] [Abstract][Full Text] [Related]
4. Serum thymidine kinase 1 activity in breast cancer.
Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
[TBL] [Abstract][Full Text] [Related]
5. Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.
McKenna PG; O'Neill KL; Abram WP; Hannigan BM
Br J Cancer; 1988 Jun; 57(6):619-22. PubMed ID: 3408646
[TBL] [Abstract][Full Text] [Related]
6. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
[TBL] [Abstract][Full Text] [Related]
8. Sensitive nonradiometric method for determining thymidine kinase 1 activity.
Ohrvik A; Lindh M; Einarsson R; Grassi J; Eriksson S
Clin Chem; 2004 Sep; 50(9):1597-606. PubMed ID: 15247154
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
10. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Li HX; Lei DS; Wang XQ; Skog S; He Q
Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
[TBL] [Abstract][Full Text] [Related]
12. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
13. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
14. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of the TK1-Specific Activity in the Early Detection of Ovarian Cancer.
Osredkar J; Jagarlamudi KK; Cviič D; Škof E; Cvjetićanin B; Zore A; Lukanović D; Eriksson S; Meglič L
Oncology; 2024; 102(1):17-29. PubMed ID: 37673047
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer.
Romain S; Christensen IJ; Chinot O; Balslev I; Rose C; Martin PM; Thorpe SM
Int J Cancer; 1995 Mar; 61(1):7-12. PubMed ID: 7705935
[TBL] [Abstract][Full Text] [Related]
17. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA.
Zehentner BK; Persing DH; Deme A; Toure P; Hawes SE; Brooks L; Feng Q; Hayes DC; Critichlow CW; Houghton RL; Kiviat NB
Clin Chem; 2004 Nov; 50(11):2069-76. PubMed ID: 15375015
[TBL] [Abstract][Full Text] [Related]
18. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
[TBL] [Abstract][Full Text] [Related]
19. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of thymidine kinase in colorectal and breast cancer.
Svobodova S; Topolcan O; Holubec L; Treska V; Sutnar A; Rupert K; Kormunda S; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1907-9. PubMed ID: 17649793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
